Clinical Trial Update: Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial evaluated arsenic trioxide in combination with etanercept for myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Etanercept (etanercept)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED